Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.

Neubauer, B L; Best, K L; Goode, R L; Heiman, M L; Hoover, D M; Robertson, D W; Sarosdy, M F; Shaar, C J; Tanzer, L R; Merriman, R L

Neubauer, B L; Best, K L; Goode, R L; Heiman, M L; Hoover, D M; Robertson, D W; Sarosdy, M F; Shaar, C J; Tanzer, L R; Merriman, R L.

Affiliation

Neubauer BL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.

Cancer Res ; 52(17): 4663-71, 1992 Sep 01.

Article in En | MEDLINE | ID: mdl-1511432

Subject(s)

Adenocarcinoma/drug therapy; Prostatic Neoplasms/drug therapy; Adenocarcinoma/pathology; Adrenal Glands/anatomy & histology; Animals; Aromatase Inhibitors; Body Weight/drug effects; Chlorobenzenes/pharmacology; Estradiol/therapeutic use; Estramustine/analogs & derivatives; Estramustine/pharmacology; Hypophysectomy; Male; Neoplasm Metastasis; Neoplasms, Experimental; Orchiectomy; Organ Size/drug effects; Prostatic Neoplasms/pathology; Pyrimidines/pharmacology; Pyrrolidines/pharmacology; Rats; Rats, Inbred Strains; Seminal Vesicles/anatomy & histology; Testis/anatomy & histology; Thiophenes/pharmacology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma Limits: Animals Language: En Journal: Cancer Res Year: 1992 Document type: Article Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links